Non Hodgkin's Lymphoma News and Research

RSS

The Non-Hodgkin lymphomas (NHLs) are a diverse group of hematologic cancers which encompass any lymphoma other than Hodgkin's Lymphoma.

Infinity and AbbVie enter into global collaboration to develop and commercialize duvelisib

Infinity Pharmaceuticals, Inc. and AbbVie Inc. today announced that they have entered into a global collaboration to develop and commercialize duvelisib (IPI-145), Infinity's oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, for the treatment of patients with cancer.

3 Sep 2014

Blood cancer patients in the UK can now benefit from Roche's MabThera SC

Patients with one of the most common forms of blood cancer can now benefit from a new injection. MabThera subcutaneous (SC), which is given to patients just beneath the skin, can be administered in approximately five minutes, compared to the current two and a half hour intravenous (IV) infusion.

6 Aug 2014

FDA approves use of Imbruvica to treat patients with chronic lymphocytic leukemia

The U.S. Food and Drug Administration today expanded the approved use of Imbruvica (ibrutinib) to treat patients with chronic lymphocytic leukemia (CLL) who carry a deletion in chromosome 17 (17p deletion), which is associated with poor responses to standard treatment for CLL. Imbruvica received a breakthrough therapy designation for this use.

29 Jul 2014

Zydelig gets FDA approval for treatment of patients with three types of blood cancers

The U.S. Food and Drug Administration today approved Zydelig (idelalisib) to treat patients with three types of blood cancers.

24 Jul 2014

Study reveals why survival for blood cancer patients still varies between regions within Europe

Failure to get the best treatment and variations in the quality of care are the most likely reasons why survival for blood cancer patients still varies widely between regions within Europe, according to the largest population-based study of survival in European adults to date, published in The Lancet Oncology.

15 Jul 2014

Medac Pharma's Rasuvo injection gets FDA approval for RA, pJIA and psoriasis

Medac Pharma, Inc., a privately held pharmaceutical company focused on the development of new molecules and improving the effectiveness of existing medicines, announced that the U.S. Food and Drug Administration has approved Rasuvo, a subcutaneous injectable methotrexate (MTX) therapy delivered in an auto-injector for rheumatoid arthritis (RA), polyarticular-course juvenile idiopathic arthritis (pJIA) and psoriasis.

14 Jul 2014

Penn’s immunotherapy receives FDA's Breakthrough Therapy designation for ALL treatment

A University of Pennsylvania-developed personalized immunotherapy has been awarded the U.S. Food and Drug Administration's Breakthrough Therapy designation for the treatment of relapsed and refractory adult and pediatric acute lymphoblastic leukemia (ALL).

7 Jul 2014

Beleodaq gets FDA approval for treatment of patients with peripheral T-cell lymphoma

The U.S. Food and Drug Administration today approved Beleodaq (belinostat) for the treatment of patients with peripheral T-cell lymphoma (PTCL), a rare and fast-growing type of non-Hodgkin lymphoma (NHL). The action was taken under the agency's accelerated approval program.

3 Jul 2014

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, a global biopharmaceutical leader, and Dermira, Inc., a privately held US-based dermatology company, announced today that they have entered into an exclusive licensing agreement for the development and future commercialization of Cimzia (certolizumab pegol) in dermatology.

3 Jul 2014

HIV-positive people with early-stage cancer less likely to get cancer treatment

HIV-infected people diagnosed with cancer are two to four times more likely to go untreated for their cancer compared to uninfected cancer patients, according to a new, large retrospective study from researchers in Penn Medicine's Abramson Cancer Center and the National Cancer Institute (NCI) published online ahead of print in the Journal of Clinical Oncology.

1 Jul 2014

Non-Hodgkin lymphoma subgroups found to have different survival rates

A Mayo Clinic-led group of researchers has discovered three subgroups of a single type of non-Hodgkin lymphoma that have markedly different survival rates. These subgroups could not be differentiated by routine pathology but only with the aid of novel genetic tests, which the research team recommends giving to all patients with ALK-negative anaplastic large-cell lymphoma (ALCL). Findings are published in the journal Blood.

27 Jun 2014

Researchers identify two oncogenes that drive the development of medulloblastoma

A new collaborative study carried out by researchers at Sanford-Burnham Medical Research Institute, UC San Diego, the German Cancer Research Center, the University of Heidelberg (Germany), and 33 other research institutions has identified two oncogenes, called GFI1 and GFI1B, that drive the development of medulloblastoma, the most common malignant brain tumor in children.

23 Jun 2014

Cancer drug offers protection against thrombosis

Case Western Reserve University researchers have discovered that an existing drug used to help cancer patients has the potential to protect thousands of others from the often-deadly impact of vascular clots.

12 Jun 2014

Mirna enrolls first patient in hematological malignancy cohort of MRX34 Phase 1 clinical trial

Mirna Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering microRNA-based Replacement Therapy to treat cancer, today announced the enrollment of the first patient in the hematological malignancy cohort of its ongoing Phase 1 clinical trial of MRX34, the company's lead product candidate and first microRNA mimic in human clinical trials in oncology.

11 Jun 2014

HCV reactivation may not worsen survival outcomes for lymphoma patients with HIV

More than a quarter of HIV+ patients are also infected with the Hepatitis C virus (HCV), which may complicate treatment and care decisions after a cancer diagnosis. The specifics of those complications haven't been well-researched in the past. Results from a new Fox Chase Cancer Center study on this patient population may start filling in that gap.

31 May 2014

Alligator Bioscience acquires rights to drug development candidate ADC-1013

BioInvent International AB (publ) (OMXS:BINV) today announced that the company has sold back all its rights to drug development candidate ADC-1013 to former partner Alligator Bioscience for an undisclosed sum.

27 May 2014

UCB announces results from PRECiSE clinical trial of Cimzia in patients with Crohn's disease

UCB announced today results from the PRECiSE 3 7-year open label extension clinical trial of Cimzia (certolizumab pegol), the longest continuous trial of an anti-TNF therapy evaluating long-term safety in Crohn's disease.

6 May 2014

Cell Therapeutics announces launch of PIXUVRI in the UK for treatment of aggressive B-cell NHL

Cell Therapeutics, Inc. today announced the launch of PIXUVRI (pixantrone), the first new treatment for adult patients in the United Kingdom (UK) with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (aggressive B-cell NHL), at the 54th annual scientific meeting of the British Society for Haematology.

29 Apr 2014

Menopausal hormone therapy may lower risk of B-cell non-Hodgkin lymphoma

Hormone therapy, which is prescribed to women for relief of menopausal symptoms such hot flashes, night sweats and vaginal dryness, has recently seen a decline in popularity (and use) due to its link to an increased risk of breast and endometrial cancer. But City of Hope researchers have found that menopausal hormone therapy may actually lower the risk of B-cell non-Hodgkin lymphoma.

8 Apr 2014

FDA grants orphan drug designation for Kite Pharma's cancer immunotherapy product

Kite Pharma, Inc., a clinical-stage biotechnology company focused on developing engineered autologous T cell therapy (eACT) products for cancer, today announced that the U.S. Food and Drug Administration Office of Orphan Products Development granted orphan drug designation for the Company's lead investigational therapy, an autologous engineered T cell product that targets CD19 expression on B cell malignancies, for the treatment of diffuse large B cell lymphoma (DLBCL).

31 Mar 2014